Heart Test Laboratories Net Income
| HSCS Stock | USD 2.99 0.17 6.03% |
As of the 8th of February, Heart Test retains the market risk adjusted performance of 0.9065, and Risk Adjusted Performance of 0.0358. Heart Test technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Heart Test Laboratories coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Heart Test is priced fairly, providing market reflects its last-minute price of 2.99 per share. Please also validate Heart Test Laboratories total risk alpha, which is currently at (0.39) to confirm the company can sustain itself at a future point.
Heart Test Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 972.3076 | Revenue | Earnings Share (6.56) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.9 M | -8.3 M | |
| Net Loss | -5.7 M | -6 M | |
| Net Loss | -7.9 M | -8.3 M | |
| Net Loss | (8.41) | (8.83) |
Heart | Net Income | Build AI portfolio with Heart Stock |
The evolution of Net Income for Heart Test Laboratories provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Heart Test compares to historical norms and industry peers.
Latest Heart Test's Net Income Growth Pattern
Below is the plot of the Net Income of Heart Test Laboratories over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Heart Test Laboratories financial statement analysis. It represents the amount of money remaining after all of Heart Test Laboratories operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Heart Test's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Heart Test's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.77 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Heart Net Income Regression Statistics
| Arithmetic Mean | (4,899,305) | |
| Coefficient Of Variation | (38.93) | |
| Mean Deviation | 1,576,476 | |
| Median | (3,811,118) | |
| Standard Deviation | 1,907,130 | |
| Sample Variance | 3.6T | |
| Range | 6.3M | |
| R-Value | (0.77) | |
| Mean Square Error | 1.6T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (290,492) | |
| Total Sum of Squares | 58.2T |
Heart Net Income History
Other Fundumenentals of Heart Test Laboratories
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Heart Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Heart Test is extremely important. It helps to project a fair market value of Heart Stock properly, considering its historical fundamentals such as Net Income. Since Heart Test's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Heart Test's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Heart Test's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Heart introduce new products? Factors like these will boost the valuation of Heart Test. Market participants price Heart higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Heart Test listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.56) | Revenue Per Share | Quarterly Revenue Growth 6.538 | Return On Assets | Return On Equity |
Understanding Heart Test Laboratories requires distinguishing between market price and book value, where the latter reflects Heart's accounting equity. The concept of intrinsic value - what Heart Test's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Heart Test's price substantially above or below its fundamental value.
Please note, there is a significant difference between Heart Test's value and its price as these two are different measures arrived at by different means. Investors typically determine if Heart Test is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Heart Test's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Heart Test 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Heart Test's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Heart Test.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Heart Test on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Heart Test Laboratories or generate 0.0% return on investment in Heart Test over 90 days. Heart Test is related to or competes with PAVmed, STRATA Skin, Matinas BioPharma, Brainstorm Cell, Autonomix Medical, Impact BioMedical, and Mainz Biomed. Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices More
Heart Test Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Heart Test's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Heart Test Laboratories upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.44 | |||
| Information Ratio | 0.0182 | |||
| Maximum Drawdown | 26.18 | |||
| Value At Risk | (7.86) | |||
| Potential Upside | 11.07 |
Heart Test Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Heart Test's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Heart Test's standard deviation. In reality, there are many statistical measures that can use Heart Test historical prices to predict the future Heart Test's volatility.| Risk Adjusted Performance | 0.0358 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0193 | |||
| Treynor Ratio | 0.8965 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Heart Test's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Heart Test February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0358 | |||
| Market Risk Adjusted Performance | 0.9065 | |||
| Mean Deviation | 4.32 | |||
| Semi Deviation | 5.11 | |||
| Downside Deviation | 5.44 | |||
| Coefficient Of Variation | 2959.89 | |||
| Standard Deviation | 5.76 | |||
| Variance | 33.23 | |||
| Information Ratio | 0.0182 | |||
| Jensen Alpha | 0.1683 | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | 0.0193 | |||
| Treynor Ratio | 0.8965 | |||
| Maximum Drawdown | 26.18 | |||
| Value At Risk | (7.86) | |||
| Potential Upside | 11.07 | |||
| Downside Variance | 29.57 | |||
| Semi Variance | 26.09 | |||
| Expected Short fall | (5.12) | |||
| Skewness | 0.0452 | |||
| Kurtosis | 1.19 |
Heart Test Laboratories Backtested Returns
Heart Test appears to be unstable, given 3 months investment horizon. Heart Test Laboratories holds Efficiency (Sharpe) Ratio of 0.0469, which attests that the entity had a 0.0469 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Heart Test Laboratories, which you can use to evaluate the volatility of the firm. Please utilize Heart Test's risk adjusted performance of 0.0358, and Market Risk Adjusted Performance of 0.9065 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Heart Test holds a performance score of 3. The company retains a Market Volatility (i.e., Beta) of 0.21, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Heart Test's returns are expected to increase less than the market. However, during the bear market, the loss of holding Heart Test is expected to be smaller as well. Please check Heart Test's coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Heart Test's current trending patterns will revert.
Auto-correlation | -0.04 |
Very weak reverse predictability
Heart Test Laboratories has very weak reverse predictability. Overlapping area represents the amount of predictability between Heart Test time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Heart Test Laboratories price movement. The serial correlation of -0.04 indicates that only as little as 4.0% of current Heart Test price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.04 | |
| Spearman Rank Test | -0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Heart Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Heart Test Laboratories reported net income of (8.77 Million). This is 102.57% lower than that of the Health Care Equipment & Supplies sector and 103.68% lower than that of the Health Care industry. The net income for all United States stocks is 101.54% higher than that of the company.
Heart Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Heart Test's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Heart Test could also be used in its relative valuation, which is a method of valuing Heart Test by comparing valuation metrics of similar companies.Heart Test is currently under evaluation in net income category among its peers.
Heart Test ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Heart Test's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Heart Test's managers, analysts, and investors.Environmental | Governance | Social |
Heart Test Institutional Holders
Institutional Holdings refers to the ownership stake in Heart Test that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Heart Test's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Heart Test's value.| Shares | Citadel Advisors Llc | 2025-06-30 | 18.7 K | Geode Capital Management, Llc | 2025-06-30 | 11.6 K | Advisory Services Network, Llc | 2025-06-30 | 10 K | Tower Research Capital Llc | 2025-06-30 | 665 | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 400 | Bank Of America Corp | 2025-06-30 | 10.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 0.0 | Ubs Group Ag | 2025-06-30 | 0.0 |
Heart Fundamentals
| Return On Equity | -2.2 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (857.13) % | ||||
| Current Valuation | 8.43 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Shares Owned By Insiders | 5.12 % | ||||
| Shares Owned By Institutions | 5.70 % | ||||
| Number Of Shares Shorted | 30.53 K | ||||
| Price To Book | 2.27 X | ||||
| Price To Sales | 1,096 X | ||||
| Revenue | 4.35 K | ||||
| Gross Profit | 5.02 K | ||||
| EBITDA | (8.14 M) | ||||
| Net Income | (8.77 M) | ||||
| Cash And Equivalents | 4.27 M | ||||
| Cash Per Share | 0.52 X | ||||
| Total Debt | 2.99 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 3.53 X | ||||
| Book Value Per Share | 1.36 X | ||||
| Cash Flow From Operations | (7.41 M) | ||||
| Short Ratio | 0.40 X | ||||
| Earnings Per Share | (6.56) X | ||||
| Target Price | 10.6 | ||||
| Number Of Employees | 15 | ||||
| Beta | 2.54 | ||||
| Market Capitalization | 9.5 M | ||||
| Total Asset | 4.22 M | ||||
| Retained Earnings | (76.13 M) | ||||
| Working Capital | (1.53 M) | ||||
| Net Asset | 4.22 M |
About Heart Test Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Heart Test Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Heart Test using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Heart Test Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.